Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04716231 · ClinicalTrials.gov registry record · Phase 3
Atacicept in Subjects With IgA Nephropathy
A Phase 3 study of IgA Nephropathy and Berger Disease, sponsored by Vera Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
- 1
- Study location
NCT04716231 is a Phase 3 study of IgA Nephropathy and Berger Disease that is active but no longer recruiting, run by Vera Therapeutics. The registered enrollment target is 376 participants, above the 130-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (189% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04716231, a Phase 3 study of IgA Nephropathy and Berger Disease, is active but no longer recruiting, sponsored by Vera Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
Conditions Studied
Interventions
- BIOLOGICAL Atacicept
- OTHER Placebo to match Atacicept
Study Locations (1)
California
- ORIGIN 3 Global Site Contact Information - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04716231
The ClinicalTrials.gov registry entry for NCT04716231 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 130-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (189% higher). The listed sponsor is Vera Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with IgA Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Atacicept is the first listed.
NCT04716231 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04716231 about?
NCT04716231 is a clinical study titled "Atacicept in Subjects With IgA Nephropathy". A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
What is the current status of trial NCT04716231?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2023-06-29. Estimated completion is 2028-07.
What conditions does trial NCT04716231 study?
This clinical trial studies the following conditions: IgA Nephropathy, Berger Disease.
What interventions are being tested in trial NCT04716231?
The interventions under investigation include: Atacicept (BIOLOGICAL), Placebo to match Atacicept (OTHER).
Who is sponsoring clinical trial NCT04716231?
This trial is sponsored by Vera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04716231 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Study of BHV-1400 in IgA Nephropathy
RECRUITING · Phase 1
-
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
RECRUITING · Phase 2
-
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
RECRUITING · Phase 4
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.